Original articleExpression of epidermal growth factor receptor in gastric carcinomas☆
Section snippets
Patients and tissue samples
We examined 413 gastric carcinomas resected consecutively at the Department of Surgery, Yamanashi Medical University between 1994 and 2000. The patients included 290 men and 123 women with an average age of 63.2 years (range, 18–90 years). This laboratory study was approved by the Institutional Review Board of Yamanashi Medical University, and written, informed consent was obtained from all patients. By using the criteria of the World Health Organization Classification of Tumors,29 the 413
Results
Positive immunostaining of the EGFR protein (1+, 2+, or 3+) was found in 43 (10.4%) of the 413 gastric carcinomas analyzed. The distinction between 1+ and negative staining was equivocal in 12 cases with variance between the 3 pathologists. High-level overexpression (2+ or 3+) was found in 9 carcinomas (2.2%) and differed from 1+ staining in that it was distinct (Figure 1A) and was graded consistently by the pathologists. Comparison of extracellular domain- and intracellular domain-specific
Discussion
In this study, high-level overexpression of EGFR was found in a small minority (2.2%) of gastric cancers. Earlier studies have reported a higher prevalence of EGFR overexpression in gastric cancers detected by IHC ranging from 18%–81%,14, 15, 16, 17, 18, 19, 20, 21 although some of these findings remain controversial. In comparison with these other studies, we observed a considerably smaller rate of overall positivity (i.e., 10.4%) and high-level overexpression. This variation might be related
References (47)
- et al.
Identification of epidermal growth factor receptors in a hyperproducing human epidermoid carcinoma cell line
J Biol Chem
(1979) - et al.
Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomasa comparative immunohistochemical and fluorescence in situ hybridization study
Mod Pathol
(2001) - et al.
Protein overexpression and gene amplification of c-erbB-2 in breast carcinomasa comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues
Hum Pathol
(2002) - et al.
The molecular biology of esophageal and gastric cancer and their precursorsoncogenes, tumor suppressor genes, and growth factors
Hum Pathol
(1994) - et al.
Increased epidermal growth factor receptors in gastric carcinomas
Gastroenterology
(1990) - et al.
The level of a transcription factor Sp1 is correlated with the expression of EGF receptor in human gastric carcinomas
Biochem Biophys Res Commun
(1992) - et al.
Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry
EMBO J
(1999) - et al.
Expression cloning of human EGF receptor complementary DNAgene amplification and three related messenger RNA products in A431 cells
Science
(1984) - et al.
Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer
Eur Respir J
(2000) - et al.
Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer
Oncogene
(1991)
Silence of chromosomal amplifications in colon cancer
Cancer Res
Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck
Br J Cancer
Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer
Int J Cancer
The epidermal growth factor receptor in human pancreatic cancer
J Pathol
EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization
J Pathol
Patterns of epidermal growth factor receptor amplification in malignant gliomas
Am J Pathol
Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo
Cancer Res
Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer
Br J Cancer
Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis
Anticancer Res
Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer
Histol Histopathol
DNA ploidy, proliferative index and EGF-R status in 130 cases of resected gastric cancera multivariate analysis
Hepatogastroenterology
Relationships among the expression of epidermal growth factor receptor, proliferating cell nuclear antigen labeling index, and lymph node metastasis in gastric cancer
Oncology
Cited by (68)
Cetuximab conjugated temozolomide-loaded poly (lactic-co-glycolic acid) nanoparticles for targeted nanomedicine in EGFR overexpressing cancer cells
2020, Journal of Drug Delivery Science and TechnologyCitation Excerpt :The epidermal growth factor receptor (EGFR) is a transmembrane protein located on cell surfaces. When engaged by one of its ligands, EGFR activates tyrosine kinase and as a result, intracellular substrates are phosphorylated [1,2]. Furthermore, these EGFR complexes initiate signaling pathways that lead to cell growth, DNA synthesis, and the proliferation of normal and malignant cells.
Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization
2014, Human PathologyCitation Excerpt :Forty gastric cancers without ERBB2 amplification were selected at random from 314 differentiated-type gastric adenocarcinomas for DNA examination. DNA from cell lines MKN7, A431, KATOIII, HSC39, and MKN45, which had previously been confirmed to have amplified ERBB2, EGFR, FGFR2, FGFR2, MYC, and MET, respectively, were used as positive controls [23,24]. MLPA analysis was performed by using 2 kits from MRC-Holland (Amsterdam, the Netherlands).
Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer
2012, European Journal of CancerCitation Excerpt :Recently, an increased understanding of the molecular basis of cancer has led to the development of specific molecular-targeted agents. The epidermal growth factor receptor (EGFR) has been found to be over-expressed in 10–63% of gastric cancers.14 EGFR over-expression is associated with tumour progression and poor prognosis in GEC patients, providing the rational for targeting this receptor in GEC.15
Myristicin Suppresses Gastric Cancer Growth via Targeting the EGFR/ ERK Signaling Pathway
2023, Current Molecular PharmacologySystematic Review and Meta-analysis of TP53, HER2/ERBB2, KRAS, APC, and PIK3CA Genes Expression Pattern in Gastric Cancer
2022, Middle East Journal of Digestive Diseases
- ☆
Supported by the Japanese Ministry of Education, Sports, Science and Culture No. C 1260157.